MedTrace Logo

Evaluating Effects of Curcumin in Moderate to Severe Asthmatics

NCT04353310 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-11-17

No results posted yet for this study

Summary

The purpose of this investigator-initiated study is to evaluate the effects of oral curcumin supplementation versus placebo in adult patients with moderate to severe asthma. Curcumin, a derivative of turmeric, has been shown in animal models to inhibit the secretion of pro-inflammatory cytokines and decrease airway constriction and hyperreactivity with only a few observational studies available in humans with discordant results.

Conditions

Interventions

DRUG

Curcumin

Curcumin 1500mg PO BID

OTHER

Placebo

identical in appearance to curcumin

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Laren Tan, MD · Loma Linda University Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2021-11-09
Completion
2021-11-09
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04353310 on ClinicalTrials.gov